## RECEIVED CENTRAL FAX CENTER

File: 11054-1:

OCT 0 3 2005

## IN THE UNITED STATES PATENT AND TRADEMARKS OFFICE

In The Matter of Patent Application:

Applicant : Narang et al

Serial No.: 10/031,874

Filing Date: November 14, 2002

Title : Single-Domain Antige-Binding Antibody Fragments

Derived from Llama Antibodies

To: The Commissioner of Patents

and Trademarks P.O. Box 1450

Alexandria, VA 22313-1450

U.S.A.

. 10/05/2005 TLO111 00000011 10031874

02 FC:1806

189.00 OP

Dear Sir:

## INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR 1.97(b)

In accordance with the duty of disclosure under 37 C.F.R. § 1.56(a) and in conformance with the procedures of 37 C.F.R. §§ 1.97-98 and M.P.E.P. § 609, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO-1449. Copies of the listed references are provided herewith.

-2-

It is respectfully requested that the information above be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

We hereby authorize you to charge the Required Fee of \$180.00 to our Mastercard Credit Card. The required Form PTO-2038 is attached herewith.

We hereby authorize you to deduct any deficiency of the fee stated above or credit to this amount to our **Deposit Account 14-0429**.

Respectfully submitted,

By: Margaret McKay

Regn No: 52,519

:sta

Tel: 613-991-6853

Date: October 3, 2005

	<u>, , , , , , , , , , , , , , , , , , , </u>					PAGE_1_	_ of _ 2
<del></del>							
Form PTO-1449 U.S. Department of Commerc			ATTY. DOCKET NO.		SERIAL NO.		
•			11054-1	10/031,874	10/031,874		
INFORMATION DISCLOSURES STATEMENT			APPLICANT .				
			TANHA et al				
			FILING DATE		GROUP		
			November 14, 2002		1642		
					•		
*EXAMINE R INITIAL	Document Number	PUBLICATION DATE	NAME	CLASS	SUBCLASS	FILING D	
	6,399,763	06/04/2002	Unilever et al	·			
	6,172,197	01/09/2001	McCafferty et al				
				•			
				•		···	
	FORE	GN PATENT I	OOCUMEN	ITS			
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	DOCOMENT NOMEDIA					YES	NO
	WO 94/04678	03/03/1994	PCT				
	WO 99/37681	07/29/1999	PCT				
	WO 99/42077 A	08/26/1999	PÇT				
	EP 0 739 981 A	10/30/1996	EP				
	EP 0 934 953 A	08/11/1999	EP				-
	WO 00 43507 A	07/27/2000	PCT				
							•
EXAMINER:		DATE CONSIDERED					
	uitial if reference considered, whether or r				e through citatio	n if not in	

## Non Patent Literature Documents (Including Author, Title, Date Pertinent Pages, Etc.)

		LAUWEREYS, M. et al., "Potent enzyme inhibitors derived from dromedary heavy-chain antibodies"; The Embo Journal, 17: 3512-3520, 1998				
		DAVIES, J. et al., "Antibody VH domains as small recognition units"; <i>Bio/Technology</i> ,				
	ļ	13: 475-479, 1995				
		NGUYEN, V. et al., "Camel heavy-chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen-binding repertoire"; The Embo Journal, 19: 921-930, 2000				
		SAMPATH, A. et al., "Versatile vectors for direct cloning and ligation-independent cloning of PCT-amplified fragments for surface display on filamentous bacteriophages"; <i>Gene</i> , 190: 5-10, 1997				
		GHAHROUDI, A., "Selection and identification of single domain antibody fragments from camel heavy-chain antibodies"; FEBS Letters, 414: 521-526, 1997				
		KREBBER, C. et al., "Co-selection of cognate antibody-antigen pairs by selectively-infective phages"; FEBS, 337: 227-231, 1995				
		HOOGENBOOM, H. et al., "Antibody phage display technology and its applications"; Immunotechnology, 4: 1-20, 1998				
- Examples		DAYE CONSIDERED				
BLANCHARD						
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP 609; draw a line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant						